Literature DB >> 22277643

Criteria to predict carriers of a novel SCN5A mutation in a large Portuguese family affected by the Brugada syndrome.

Luis Ferreira Santos1, Bruno Rodrigues, Davide Moreira, Emanuel Correia, Luis Nunes, Antonio Costa, Luis Elvas, Telmo Pereira, Jose Carlos Machado, Sergio Castedo, Carla Henriques, Ana Matos, Jorge Oliveira Santos.   

Abstract

AIMS: Brugada syndrome (BrS) is a life-threatening arrhythmia disorder associated with autosomal-dominant mutations in the SCN5A gene. We aimed to characterize the diagnostic challenges and clinical manifestations of a novel SCN5A mutation associated with BrS. METHODS AND
RESULTS: From a novel SCN5A mutation (c.664C>T; p.Arg222X) identified in a proband with the characteristic electrocardiographic pattern and the history of sudden collapse, 122 family members were studied including 40 carriers of the mutation. The electrocardiographic diagnosis of BrS requires type 1 Brugada electrocardiogram (ECG) pattern in >1 right precordial lead (V1-V3), but recently an isolated lead with coved-type ECG was proposed to be enough for the diagnosis. In this family, these proposed criteria (PC) were more sensitive in detecting mutation carriers than the conventional criteria without repercussion on the specificity. Carriers had, on average, longer P-wave duration, PR, and QRS intervals and higher transmural dispersion of repolarization. The prevalence of late potentials was higher in carriers, and individual signal average ECG (SAECG) parameters (QRSf, LAS, and RMS40) also were related to SCN5A gene mutation. Three non-carriers were found to be affected by BrS, two with a spontaneous type 1 ECG with alternative placement of the precordial electrodes, and one only after the pharmacological provocative test, suggesting that other genes may play a role in the pathophysiology of this disease.
CONCLUSION: The PC for BrS diagnosis should be implemented. Some parameters from the spontaneous ECG and the SAECG are more effective tools than the characteristic repolarization pattern to discriminate between carriers of SCN5A mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22277643     DOI: 10.1093/europace/eur421

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

1.  Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.

Authors:  Andrew M Glazer; Giovanni Davogustto; Christian M Shaffer; Carlos G Vanoye; Reshma R Desai; Eric H Farber-Eger; Ozan Dikilitas; Ning Shang; Jennifer A Pacheco; Tao Yang; Ayesha Muhammad; Jonathan D Mosley; Sara L Van Driest; Quinn S Wells; Lauren Lee Shaffer; Olivia R Kalash; Yuko Wada; Sarah Bland; Zachary T Yoneda; Devyn W Mitchell; Brett M Kroncke; Iftikhar J Kullo; Gail P Jarvik; Adam S Gordon; Eric B Larson; Teri A Manolio; Tooraj Mirshahi; Jonathan Z Luo; Daniel Schaid; Bahram Namjou; Tarek Alsaied; Rajbir Singh; Ashutosh Singhal; Cong Liu; Chunhua Weng; George Hripcsak; James D Ralston; Elizabeth M McNally; Wendy K Chung; David S Carrell; Kathleen A Leppig; Hakon Hakonarson; Patrick Sleiman; Sunghwan Sohn; Joseph Glessner; Joshua Denny; Wei-Qi Wei; Alfred L George; M Benjamin Shoemaker; Dan M Roden
Journal:  Circulation       Date:  2021-12-21       Impact factor: 39.918

2.  Enhanced risk profiling of implanted defibrillator shocks with circulating SCN5A mRNA splicing variants: a pilot trial.

Authors:  Ge Gao; Vikram Brahmanandam; Mihai Raicu; Lianzhi Gu; Li Zhou; Srinivasan Kasturirangan; Anish Shah; Smita I Negi; Melissa R Wood; Ankit A Desai; Antone Tatooles; Alan Schwartz; Samuel C Dudley
Journal:  J Am Coll Cardiol       Date:  2014-04-02       Impact factor: 24.094

3.  Diagnostic dilemmas: overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathy.

Authors:  Mark G Hoogendijk
Journal:  Front Physiol       Date:  2012-05-23       Impact factor: 4.566

Review 4.  Brugada syndrome in children - Stepping into unchartered territory.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2017 Sep-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.